<unk>  has been provisionally approved for approximately 8% of all DMD patients amenable to exon 53 skipping. It works by inducing exon skipping in the dystrophin gene and thereby increasing the amount of dystrophin protein available to muscle fibers.
Golodirsen
Viltolarsen
Oleandrin
Quinagolide
Pergolide
Travoprost
Casimersen
Tolevamer